Company Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio.
The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 1980 |
| IPO Date | Jun 3, 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,314 |
| CEO | Douglas Ingram |
Contact Details
Address: 215 First Street, Suite 415 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 274 4000 |
| Website | sarepta.com |
Stock Details
| Ticker Symbol | SRPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000873303 |
| CUSIP Number | 803607100 |
| ISIN Number | US8036071004 |
| Employer ID | 93-0797222 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas S. Ingram Esq. | President, Chief Executive Officer and Director |
| Ian Michael Estepan | Executive Vice President and Chief Financial Officer |
| Bilal Arif | Executive Vice President and Chief Technical Operations Officer |
| Dr. Louise R. Rodino-Klapac Ph.D. | Executive Vice President, Chief Scientific Officer and Head of Research and Development |
| Ryan E. Brown J.D. | Executive Vice President, Chief General Counsel and Corporate Secretary |
| Francesca T. Nolan | Executive Director of Investor Relations and Corporate Communications |
| Alison Nasisi | Executive Vice President and Chief People Officer |
| Dr. Diane L. Berry Ph.D. | Executive Vice President and Chief of Global Policy and Advocacy Officer |
| Dallan Murray | Executive Vice President and Chief Customer Officer |
| Will Tilton | Senior Vice President, Head of Strategy and Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2024 | 8-K | Current Report |
| Aug 30, 2024 | 144 | Filing |
| Aug 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Jun 25, 2024 | 144 | Filing |
| Jun 25, 2024 | 144 | Filing |
| Jun 24, 2024 | 144 | Filing |
| Jun 7, 2024 | 8-K | Current Report |
| Jun 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 1, 2024 | 10-Q | Quarterly Report |